Open AccessCost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
Author(s) -
Taru Hallinen,
EJ Soini,
Christian Asseburg,
Miika Linna,
Pia Eloranta,
S. Pohjola Sintonen,
Mikko Kosunen
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s317078
Subject(s) - apixaban , rivaroxaban , dabigatran , medicine , warfarin , cost effectiveness , euros , quality adjusted life year , atrial fibrillation , risk analysis (engineering) , philosophy , humanities
Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in Finland. DOACs have been shown to be cost-effective in comparison to warfarin, but published evidence of relative cost-effectiveness between DOACs is still scarce and mostly based on indirect comparisons of clinical trial evidence. The aim of this study was to compare the cost-effectiveness of apixaban to dabigatran, rivaroxaban and warfarin in a Finnish setting using real-life evidence where available.